Recent Updates
Recently added Catalysts
PCRX Positive Sentiment Score: 70/100

Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

Key Takeaway: Pacira BioSciences announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, scheduled for April 19, 2023. The event will feature an analyst-led fireside chat, and a live audio feed will be available on the company's website. Pacira is focused on advancing non-opioid treatment options, with three commercial-stage products aimed at pain management and reducing opioid dependence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pacira is participating in a notable healthcare conference.
  • The company's commitment to provide non-opioid options is a positive development.
  • Pacira has three commercial-stage non-opioid treatments, indicating strong pipeline.

Full Press Release Details

TAMPA, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 22nd Annual Needham Virtual Healthcare Conference at 10:15 AM ET on Wednesday, April 19, 2023. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.

Contact Data

Contact

With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.

Frequently Asked Questions

When is Pacira BioSciences participating in the Needham Conference?

Pacira BioSciences will participate in the Needham Conference on April 19, 2023.

How can I access the live event of Pacira's conference participation?

The live audio can be accessed on the company's Events page at investor.pacira.com.

What are the main non-opioid treatments offered by Pacira?

Pacira offers EXPAREL®, ZILRETTA®, and ioveraº® as non-opioid treatments.

What condition does Pacira address with its treatments?

Pacira's treatments address conditions like chronic pain, spasticity, and more.

What is Pacira's mission regarding opioid use?

Pacira aims to redefine opioids as rescue therapy and reduce their overreliance.

Last updated: Apr 12, 2023